La cadena de opciones muestra datos clave de las opciones de acciones de Terns Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Terns Pharma..

Terns Pharma (NASDAQ:TERN) Bolsa, Cadena de Opciones

TERNS PHARMACEUTICALS INC

Terns Pharma

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharmaceuticals Inc

Tern PLC

TERNIUM ARGENTINA S A by TERNIUM ARGENTINA S A

Terna Energy SA

Terna Energy SA ADR

TRASMISSIONE ELECTR ORD by Terna Rete Elettrica Nazionale SPA

Terna SpA

TERNA RETE ELETTRICA ADR by Terna Rete Elettrica Nazionale SPA

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Ternium SA

Ternoa

Content Warning: This article discusses a news story involving suicidal thoughts. Please be mindful as you proceed.
In a recent episode of The Joe Rogan Experience on Thursday, Harvard historian Rebecca Lemov discussed an experiment conducted by Facebook in 2012.
What Happened: A 2012 Facebook experiment that altered user news feeds to study emotional contagion had also sparked a U.K. investigation and raised ethical concerns about privacy and manipulation. 
Lemov elaborated how the social media giant altered the news feeds of nearly 700,000 users without their consent to study emotional contagion, modifying posts to be more positive or negative.
A 2014 <a href="https://www.pnas.org/doi/full/10.1073/pnas.1320040111">study </a>published in the Proceedings of the National Academy of Sciences confirmed the experiment&#8217;s findings, showing that decreasing positive posts resulted in more negative user content and vice versa. This demonstrated that social media can influence emotions on a large scale.
Meta did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Joe Rogan Experience #2322 - Rebecca Lemov" width="500" height="281" src="https://www.youtube.com/embed/qDkHCaNAo_w?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
One user even linked their suicidal thoughts to the altered feed, according to Lemov. The study found that emotions can spread through emotional contagion, leading people to feel similar emotions unconsciously. Although the study mentioned no case of suicidal thoughts. 
The experiment prompted a British government probe into possible sanctions over its global impact and amid the escalating row, Facebook's then Chief Operating Officer Sheryl Sandberg admitted, "We communicated really badly on this subject&#8230;We take privacy at Facebook really seriously."
In this context, Lemov stated, &#8220;2012 was kind of an important point in the development of social media.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45440970/pepe-rallies-40-in-7-days-outpaces-dogecoin-shiba-inu-whats-next" target="_blank" rel="noreferrer noopener">Pepe Rallies 40% In 7 Days Outpaces Dogecoin, Shiba Inu: What&#8217;s Next? &#8211; Benzinga</a>
Why It Matters: Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), the parent of Facebook, is not new to debates surrounding its user data handling and privacy policies. On Wednesday, the Austrian advocacy group, NOYB, announced that it is <a href="https://www.benzinga.com/25/05/45406329/austrian-group-questions-metas-legitimate-interest-in-using-eu-data-for-ai-threatens-legal-action-over-200-billion-making-money-is-more-important-than-the-rights-of-its-users">preparing </a>to seek an injunction against Meta, potentially leading to billion-euro damages claims. This action is in response to Meta's plans to use Europeans' personal data for AI training.
A March report also revealed, through court filings, that Meta has been generating profits from its Llama AI models via revenue-sharing deals with hosting companies.
This revelation also comes in the wake of a landmark antitrust trial where CEO Mark Zuckerberg <a href="https://www.benzinga.com/25/04/44807557/mark-zuckerberg-proposed-wiping-all-friends-connections-and-make-users-start-again-to-keep-facebook-culturally-relevant-antitrust-trial-reveals">testified </a>about a previously unimplemented plan to reset all Facebook users' connections without their consent in 2022 to give the dying platform a new boost.
Meta holds a momentum rating of 88.49% and a growth rating of 76.06%, according to&nbsp;<a href="https://www.benzinga.com/quote/META" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. 
The shares of Meta lost 2.35% to close at $643.88 on Thursday. Over the past year, the stock surged 36.06%.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45314762/charlie-munger-was-once-asked-why-warren-buffett-was-so-much-richer-and-replied-he-got-an-earlier-start-before-adding-why-was-albert-einstein-poorer-than-i-was" target="_blank" rel="noreferrer noopener">Charlie Munger Was Once Asked Why Warren Buffett Was So Much Richer — He Replied, &#8216;He Got An Earlier Start,&#8217; Then Added, &#8216;Why Was Albert Einstein Poorer Than I Was?&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

News

Markets

Tech

Harvard Historian Tells Joe Rogan How Facebook's Controversial 2012 Emotion Experiment Reportedly Triggered Suicidal Thoughts In Some Users

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Largo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGO#NASDAQ">LGO</a>) with a Buy and lowers the price target from $3.9 to $3.7.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Largo, Lowers Price Target to $3.7

Telsey Advisory Group analyst Joseph Feldman maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Outperform and lowers the price target from $145 to $130.

Telsey Advisory Group Maintains Outperform on Target, Lowers Price Target to $130

AMST

Amesite Says AI App NurseMagic Drives 2.4x Revenue Growth QoQ In Q3 While Cutting Costs

Needham analyst John Todaro reiterates Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and maintains $16 price target.

Reiteration

Core Scientific, Inc. - Class A Common Stock

CORZ

Needham Reiterates Buy on Core Scientific, Maintains $16 Price Target

<a href="https://www.bloomberg.com/news/articles/2025-05-16/lidar-maker-hesai-is-said-to-confidentially-file-for-hk-listing" title="https://www.bloomberg.com/news/articles/2025-05-16/lidar-maker-hesai-is-said-to-confidentially-file-for-hk-listing">https://www.bloomberg.com/news/articles/2025-05-16/lidar-maker-hesai-is-said-to-confidentially-file-for-hk-listing</a>

Rumors

HSAI

Bloomberg Reported Earlier, Lidar Maker Hesai Is Said to Confidentially File for HK Listing

A beat on earnings, soaring margins, and fresh buyback authorizations weren&#8217;t enough for investors of Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), as they remain fixated on China, volatility, and a widening guidance.
What Happened: Shares of California-based Applied Materials are down 5.83% pre-market, following the company&#8217;s <a href="https://www.benzinga.com/news/earnings/25/05/45453681/applied-materials-q2-earnings-revenue-miss-eps-beat-solid-guidance-no-significant-changes-to-customer-demand">second quarter earnings</a> release on Thursday. 
The company, which supplies capital equipment to the semiconductor industry, posted $2.39 per share in earnings, beating consensus estimates by $0.08. Gross profit margins stood at 49.2%, the highest recorded since the year 2000, &#8220;primarily driven by a favorable mix of our products and business segments,&#8221; says CFO Brice Hill.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45461488/walmart-e-commerce-turns-profitable-for-the-first-time-despite-reduced-tariffs-ceo-says-full-impact-cant-be-absorbed-price-hikes-likely">Walmart E-Commerce Turns Profitable For The First Time: Despite Reduced Tariffs, CEO Says Full Impact Can&#8217;t Be Absorbed, Price Hikes Likely</a>
During the quarter, it returned $2 billion to investors in the form of dividends and stock buybacks, having bought back &#8220;approximately 1.4% of total shares outstanding.&#8221; Besides this, Applied Materials approved an additional $10 billion in buyback authorizations, bringing its total pending authorizations to $15.9 billion for future repurchases.
Yet, investors remained fixated on a handful of negatives during the quarter, starting with the widening of its revenue outlook for the third quarter by $100 million, to factor in macroeconomic and trade-related volatility. &#8220;We widened our range by $100 million… and so we thought it was a good time to widen the range,&#8221; Hill said during the call.
China also remained a flashpoint with continued headwinds from trade restrictions affecting sales of both equipment and services. &#8220;In the near term, that business is down from where it was at previously,&#8221; said CEO Gary Dickerson, referring to the company's 200mm tool business tied to power electronics, much of which is exposed to China.
Why It Matters: Market reactions aside, the company had a <a href="https://www.benzinga.com/news/earnings/25/05/45453681/applied-materials-q2-earnings-revenue-miss-eps-beat-solid-guidance-no-significant-changes-to-customer-demand">strong second quarter</a> performance, with $7.1 billion in revenue, up 6.83% year-over-year, and just a smidge short of consensus estimates at $7.13 billion. 
Profits stood at $2.39 per share, coming in ahead of estimates at $2.31. The company&#8217;s CFO, Hill said during the results that &#8220;Despite the dynamic economic and trade environment, we have not seen significant changes to customer demand and are well-equipped to navigate evolving conditions with our robust global supply chain and diversified manufacturing footprint.&#8221;
Price Action: The stock was up 0.35% on Thursday, at $174.75 per share, but is down 6.19% pre-market, following its earnings release.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="136" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16053718/Screenshot-2025-05-16-at-3.07.04-PM-1024x136.png" alt="" class="wp-image-917671" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16053718/Screenshot-2025-05-16-at-3.07.04-PM-1024x136.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16053718/Screenshot-2025-05-16-at-3.07.04-PM-300x40.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16053718/Screenshot-2025-05-16-at-3.07.04-PM-768x102.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16053718/Screenshot-2025-05-16-at-3.07.04-PM-1536x204.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16053718/Screenshot-2025-05-16-at-3.07.04-PM.png 1612w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Benzinga&#8217;s Edge Stock Rankings show that AMAT has a strong price trend in the short and medium terms, but is unfavorable in the long run. Other key metrics and more comprehensive insights are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
Image Via Shutterstock
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45462404/trump-unveils-over-200-billion-worth-of-deals-with-uae-including-major-etihad-airways-commitment">Trump Announces $200 Billion In US-UAE Deals, Etihad Orders 28 Boeing Jets Worth $14.5 Billion</a></li>
</ul>

Earnings

Equities

AMAT

Applied Materials Falls Over 6% In Pre-Market Trading On Friday, Despite Earnings Beat And Record Margins As Investors Focus On China Headwinds And Widened Outlook

Needham analyst Mayank Tandon maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Buy and lowers the price target from $130 to $115.

GLOB

Needham Maintains Buy on Globant, Lowers Price Target to $115

HC Wainwright &amp; Co. analyst Scott Buck reiterates Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy and maintains $11.5 price target.

WKSP

HC Wainwright & Co. Reiterates Buy on Worksport, Maintains $11.5 Price Target

TOPW

Top Win Rebrands Corporate Name As AsiaStrategy, Launches Digital Assets Treasury Strategy To Tap Asia's Rapidly Growing Web3 Ecosystem

Needham analyst John Todaro maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and raises the price target from $13 to $17.

BTDR

Needham Maintains Buy on Bitdeer Technologies, Raises Price Target to $17

CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today delivered three oral presentations on its SYNGAP1-related disorders and Urea Cycle Disorders (UCDs) programs and shared favorable safety and pharmacokinetics data from the ongoing Phase 1 trial of CMP-CPS-001 in healthy volunteers at the 28th Annual Meeting of the American Society of Gene and Cell Therapy, taking place in New Orleans, May 13 – 17, 2025.

CAMP

CAMP4 Unveils SYNGAP1 And Urea Cycle Disorder Data At ASGCT 2024, Highlighting Protein Boost And Safety Progress

U.S. stock futures advanced on Friday after a mixed close on Thursday. Futures of major benchmark indices were trading higher in premarket.
The S&amp;P 500 index recorded its fourth day of gains on Thursday after turning positive for the year at the beginning of the week.
Jerome Powell, Federal Reserve Chair, indicated Thursday that the Fed is r<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">eassessing its inflation and employment strategies</a>, suggesting potential shifts in policy following a comprehensive review scheduled for 2025. 
"Participants have indicated that they thought it would be appropriate to reconsider the language around [labor market] shortfalls," Powell said, referring to how the Fed talks about employment in its official strategy.
Nasdaq dropped after continued positive momentum from <a href="https://www.benzinga.com/25/05/45462404/trump-unveils-over-200-billion-worth-of-deals-with-uae-including-major-etihad-airways-commitment">partnerships with the Middle East</a> during the U.S.-Saudi Investment Forum. 
Meanwhile, the 10-year Treasury bond yielded 4.40% and the two-year bond was at 4.93%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 91.8% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.33%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.23%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.23%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.40%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Friday. The SPY was up 0.14% to $591.31, while the QQQ advanced 0.16% to $520.06, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Led by strong gains in utilities, consumer staples, and real estate, most sectors within the S&amp;P 500 finished Thursday in positive territory, contributing to the index&#8217;s fourth consecutive session of gains.
However, consumer discretionary and communication services stocks diverged from the broader market, ending the day lower.
Overall, the S&amp;P 500 has climbed approximately 4.5% week-to-date, followed by a roughly 2.6% increase for the Dow and a significant 6.6% rise for the Nasdaq.
Notably, tech giants like Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) have seen substantial weekly gains of around 15% each, with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) also adding around 6% and 7%, respectively.
In other news, Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) reported stronger-than-anticipated first-quarter earnings, while Foot Locker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) shares surged around 86% following an agreement for acquisition by DICK&#8217;s Sporting Goods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>).
On the economic front, initial jobless claims remained steady, U.S. retail sales saw a modest 0.1% monthly increase in April, and U.S. producer prices unexpectedly declined by 0.5% in April.
The Dow Jones index advanced 272 points or 0.65% to 42,322.75, whereas the S&amp;P 500 index rose 0.41% to 5,916.93. Nasdaq Composite ended 0.18% lower at 19,112.32, and the small-cap gauge, Russell 2000, ended 0.52% higher at 2,094.69.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.18%</td>
<td>19,112.32</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.41%</td>
<td>5,916.93</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.65%</td>
<td>42,322.75</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.52%</td>
<td>2,094.69</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ed Yardeni of Yardeni Research said in his QuickTakes note that Fed Chair Powell &#8220;poked a stick&#8221; at the White House following his speech on Thursday.
Yardeni pointed out that Powell implied that the bond yields might stay elevated as a result of more frequent &#8220;supply shocks,&#8221; like tariffs.
&#8220;Higher real rates may also reflect the possibility that inflation could be more volatile going forward than in the inter-crisis period of the 2010s,&#8221; Powell said in prepared remarks for the Thomas Laubach Research Conference in Washington, D.C.
Yardeni said, &#8220;Sounds like Powell is expecting more frequent bouts of stagflation, which was associated with supply shocks in the past.&#8221;
&#8220;The stock and bond markets didn&#8217;t react much to the speech partly because today&#8217;s batch of indicators were mostly ambiguous about the near-term prospects for stagflation,&#8221; he added.
As the PPI declined in April, Louis Navellier of Navellier &amp; Associates said, &#8220;The PPI demonstrated that despite recent trade chaos, wholesale prices are falling from lackluster economic activity and surplus goods that have been &#8216;dumped&#8217; in the U.S.&#8221;
Meanwhile, commenting on the declining PPI, Jamie Cox, the managing partner at Harris Financial Group, added, &#8220;If you are in the stagflation camp, these data aren't confirming your thesis. While growth is slowing, disinflation remains intact.&#8221;
Speaking about the S&amp;P 500 earnings so far, Navellier said, &#8220;Now that 90% of the companies in the S&amp;P 500 have announced their first quarter results, earnings are running at an 11.2% annual pace, which represents the seventh straight quarter of improving earnings growth.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul class="wp-block-list">
<li>April&#8217;s import price index, housing starts, and building permit data will be released by 8:30 a.m. ET.</li>
</ul>
<ul class="wp-block-list">
<li>The preliminary consumer sentiment for May will be released by 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Flowers Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>) fell 2.17% in premarket on Friday as analysts expect it to report quarterly earnings of 38 cents per share on revenue of $1.60 billion, before the opening bell.</li>
</ul>
<ul class="wp-block-list">
<li>Brady Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>) rose 1.77% as Wall Street expects it to report earnings before the opening bell. It is expected to post earnings of $1.22 per share on revenue of $386.81 million.</li>
</ul>
<ul class="wp-block-list">
<li>RBC Bearings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) declined 0.56% as analysts expect it to report quarterly earnings of $2.70 per share on revenue of $440.26 million, before the opening bell.</li>
</ul>
<ul class="wp-block-list">
<li>Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) fell 3.59% after the company guided for its first quarter net bookings to be in a range of $1.25 billion to $1.30 billion and full fiscal-year net bookings to be in a range of $5.90 billion to $6.00 billion.</li>
</ul>
<ul class="wp-block-list">
<li>Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) dropped 6.19% after a mixed second quarter. The earnings per share were better than expected, while sales missed estimates.</li>
</ul>
<ul class="wp-block-list">
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) was up 2.85% after launching a fully driverless robotaxi trial operation in Abu Dhabi.</li>
</ul>
<ul class="wp-block-list">
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) jumped 5.41% after acquiring natural gas assets worth $1.9 billion.</li>
</ul>
<ul class="wp-block-list">
<li>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) was 0.07% below flatline after the report of a delayed rollout for its AI model update.</li>
</ul>
<ul class="wp-block-list">
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) zoomed 68.98% after it finished administering doses to patients in the Phase 2 segment of its trial for Obstructive Sleep Apnea (OSA).</li>
</ul>
<ul class="wp-block-list">
<li>Origin Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) slumped 30.80% after the company reported a year-over-year decrease in first-quarter financial results and cut its FY26 sales guidance below estimates.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.19% to hover around $61.50 per barrel.
Gold Spot US Dollar fell 0.96% to hover around $3,208.84 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.19% at the 100.6880 level.
Asian markets ended lower on Friday except South Korea's Kospi and Australia's ASX 200 index. Japan's Nikkei 225, Hong Kong's Hang Seng, India's S&amp;P BSE Sensex, and China&#8217;s CSI 300 indices declined. European markets were higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest">Warren Buffett Shows How Patience Pays: 98% Of His $160 Billion Wealth Came After Turning 65, Thanks The Power Of &#8216;Compound Interest&#8217;</a></li>
</ul>
Photo: Shutterstock

Economics

Federal Reserve

AMZN

GOOG

GOOGL

IXHL

NVDA

ORGN

TSLA

TTWO

Wall Street Poised To Open Higher After S&P 500's 4-Day Run: 'Sounds Like Powell Is Expecting More Frequent Bouts Of Stagflation,' Cautions Expert

HC Wainwright &amp; Co. analyst Scott Buck reiterates Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) with a Buy and maintains $12 price target.

KSCP

HC Wainwright & Co. Reiterates Buy on Knightscope, Maintains $12 Price Target

OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.09) by 100 percent.

Earnings Misses

OSTX

OS Therapies Q1 EPS $(0.18) Misses $(0.09) Estimate

Needham analyst Serge Belanger reiterates Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) from Hold to Hold.

OMER

Needham Reiterates Hold on Omerosto Hold

Macro Economic Events

Econ #s

Eurozone Trade Balance For March 36.8B Vs. 17.5B Est.; 24.8B (Revised) Prior

NANO Nuclear Eyes Progress On KRONOS MMR Demo Reactors In U.S. And Canada; UIUC Permit Application Steps Expected In 2025

NANO Nuclear Reports H1 2025 With $108.4M Raised In Financing Activities; Company Says It Has Achieved Microreactor Milestones, Westchester Demo Launch, MSCI Inclusion & Key Hires

<a href="https://www.bloomberg.com/news/articles/2025-05-16/charter-is-in-talks-to-combine-with-rival-cox-communications?embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-05-16/charter-is-in-talks-to-combine-with-rival-cox-communications?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-16/charter-is-in-talks-to-combine-with-rival-cox-communications?embedded-checkout=true</a>

CHTR

Bloomberg Reported Earlier, Charter Is In Talks To Merge With Cox Communications

Management

Press Releases

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Health Care

General

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Comments

Terns Pharma

Terns Pharma (TERN) Opciones

Terns Pharma (NASDAQ:TERN) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL